Teladoc Health (NYSE:TDOC) Announces Earnings Results, Beats Estimates By $0.03 EPS

Teladoc Health (NYSE:TDOC) released its earnings results on Wednesday. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03, Zacks reports. The company had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health’s revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.19) EPS. Teladoc Health updated its Q3 2026 guidance to -0.300–0.200 EPS and its FY 2026 guidance to -1.000–0.750 EPS.

Here are the key takeaways from Teladoc Health’s conference call:

• BetterHelp’s outlook was reduced: 2026 segment revenue is now expected at $770 million–$830 million as U.S. cash-pay revenue declines faster than anticipated, driven by a quicker shift toward insurance, lower advertising, and provider-capacity constraints.
• BetterHelp’s insurance business is gaining traction, with more than 8,000 credentialed providers, over $150 million of contracted in-network lives, and more than 20,000 weekly insurance sessions representing an annualized revenue run rate above $110 million.
• Management accelerated BetterHelp’s insurance rollout to all 50 states and Washington, D.C., while redirecting marketing and operating resources toward U.S. insurance; however, executives said the timing of closing capacity gaps remains uncertain and expect continued cash-pay pressure.
• Integrated Care delivered solid results: revenue rose 0.7% to $394 million, adjusted EBITDA increased 13.6% to $65 million, chronic-care enrollment grew 14% year over year to 1.27 million, and full-year EBITDA margin guidance was raised.
• Teladoc launched Teladoc One, a unified AI-enabled care model spanning clinicians, specialists, therapists, coaches, and dieticians, with broad availability planned for January 2027 beginning in cardiometabolic care.

Teladoc Health Stock Down 27.8%

NYSE TDOC traded down $2.56 on Thursday, hitting $6.62. 5,508,773 shares of the stock were exchanged, compared to its average volume of 5,367,161. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The company has a 50-day moving average price of $8.21 and a 200-day moving average price of $6.55. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The company has a market cap of $1.20 billion, a PE ratio of -6.83 and a beta of 2.10.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc’s second-quarter loss of $0.21 per share was better than the consensus estimate of a $0.24 loss. Cost controls also helped narrow the company’s first-half net loss to $102.75 million, while operating cash flow reached $64.7 million. Teladoc Health Reports Second Quarter 2026 Results
• Neutral Sentiment: The company ended the quarter with $774.3 million in cash and equivalents, providing liquidity to fund operations and restructuring efforts. However, Teladoc remains unprofitable, with a $38.9 million quarterly net loss and negative margins.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing analyst expectations. The decline suggests that improved cost efficiency is not yet offsetting weakness in the company’s core growth drivers. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Negative Sentiment: Teladoc reduced its full-year 2026 revenue outlook to approximately $2.4 billion, below the roughly $2.5 billion analyst consensus. Its third-quarter revenue forecast of $569 million to $609 million was also well below expectations, while projected EPS of negative $0.30 to negative $0.20 was weaker than the consensus loss estimate. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Management cited changing demand patterns at its BetterHelp mental-health unit, adding to investor worries about the segment’s growth and the company’s ability to return to sustained profitability. The stock subsequently decreased sharply as investors focused on the revenue miss and soft outlook.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup raised their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Bank of America boosted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group upped their price objective on Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teladoc Health presently has an average rating of “Hold” and a consensus target price of $7.57.

Insider Activity

In other news, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the sale, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the transaction, the insider owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. The trade was a 6.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock valued at $299,058 over the last quarter. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its stake in Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock valued at $52,459,000 after purchasing an additional 605,061 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Teladoc Health by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after buying an additional 18,394 shares during the last quarter. Nuveen LLC raised its stake in Teladoc Health by 38.7% during the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock worth $18,618,000 after acquiring an additional 742,240 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Teladoc Health by 11.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after acquiring an additional 227,385 shares in the last quarter. Finally, Man Group plc lifted its position in Teladoc Health by 113.8% in the fourth quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock valued at $11,344,000 after acquiring an additional 862,454 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.